NEWARK, Calif., May 13, 2019 — Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced that Avanish Vellanki, chairman and chief executive officer, will present a corporate overview at the UBS Global Healthcare Conference, being held in New York, NY on May 20th-22nd.
UBS Global Healthcare Conference
Date: Monday, May 20th
Time: 11:00 a.m. Eastern Time
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com
Cait Williamson, Ph.D.
LifeSci Public Relations